LH
Labcorp Holdings Inc.
Medical - Diagnostics & Research
Market Cap$21.14B
5Y Perf.+71.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LH vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+37.2%
LH vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LH | TMO |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $21.14B | $175.76B |
| Revenue (TTM) | $14.14B | $45.20B |
| Net Income (TTM) | $942M | $6.86B |
| Gross Margin | 27.8% | 39.4% |
| Operating Margin | 11.0% | 17.8% |
| Forward P/E | 14.5x | 19.0x |
| Total Debt | $7.20B | $40.85B |
| Cash & Equiv. | $532M | $9.86B |
LH vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LH
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Labcorp Holdings In… (LH) | 100 | 171.3 | +71.3% |
| Thermo Fisher Scien… (TMO) | 100 | 137.2 | +37.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LH vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LH leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Thermo Fisher Scientific Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LH
Labcorp Holdings Inc.
The Income Pick
LH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.52, yield 1.1%
- Rev growth 7.2%, EPS growth 18.3%, 3Y rev CAGR 5.6%
- Lower volatility, beta 0.52, Low D/E 83.4%, current ratio 1.42x
Best for: income & stability and growth exposure
TMO
Thermo Fisher Scientific Inc.
The Long-Run Compounder
TMO is the clearest fit if your priority is long-term compounding.
- 229.1% 10Y total return vs LH's 150.9%
- 15.2% margin vs LH's 6.7%
- +16.6% vs LH's +6.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LH | 7.2% revenue growth vs TMO's 3.9% |
| Value | LH | Lower P/E (14.5x vs 19.0x) |
| Quality / Margins | TMO | 15.2% margin vs LH's 6.7% |
| Stability / Safety | LH | Beta 0.52 vs TMO's 1.10 |
| Dividends | LH | 1.1% yield, vs TMO's 0.4% |
| Momentum (1Y) | TMO | +16.6% vs LH's +6.5% |
| Efficiency (ROA) | TMO | 6.4% ROA vs LH's 5.1%, ROIC 7.5% vs 7.8% |
LH vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
LH vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLHLAGGINGTMO
TMOThermo Fisher Scienti…
1leads
LHLabcorp Holdings Inc.
4leads
6 Total Categories
CATEGORYLEADERvs TMOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO5/6
Valuation MetricsMultiples, price ratios, and targets
LH6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LH6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LH4/6
Risk & VolatilityBeta, volatility, and downside exposure
LH2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 3.2x LH's $14.1B. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to LH's 6.7%.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $14.1B | $45.2B |
| EBITDAEarnings before interest/tax | $2.2B | $10.5B |
| Net IncomeAfter-tax profit | $942M | $6.9B |
| Free Cash FlowCash after capex | $1.4B | $6.7B |
| Gross MarginGross profit ÷ Revenue | +27.8% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +11.0% | +17.8% |
| Net MarginNet income ÷ Revenue | +6.7% | +15.2% |
| FCF MarginFCF ÷ Revenue | +9.8% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.8% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +32.9% | +11.3% |
TMO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
LH leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 24.6x trailing earnings, LH trades at a 8% valuation discount to TMO's 26.7x P/E. On an enterprise value basis, LH's 12.7x EV/EBITDA is more attractive than TMO's 19.0x.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $21.1B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $27.8B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 24.56x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.45x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | 12.66x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 1.52x | 3.94x |
| Price / BookPrice ÷ Book value/share | 2.49x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 17.53x | 27.93x |
LH leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
LH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $11 for LH. TMO carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to LH's 0.83x. On the Piotroski fundamental quality scale (0–9), LH scores 7/9 vs TMO's 6/9, reflecting strong financial health.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | +10.9% | +13.2% |
| ROA (TTM)Return on assets | +5.1% | +6.4% |
| ROICReturn on invested capital | +7.8% | +7.5% |
| ROCEReturn on capital employed | +9.9% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.83x | 0.76x |
| Net DebtTotal debt minus cash | $6.7B | $31.0B |
| Cash & Equiv.Liquid assets | $532M | $9.9B |
| Total DebtShort + long-term debt | $7.2B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 6.22x | 5.89x |
LH leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LH leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LH five years ago would be worth $11,216 today (with dividends reinvested), compared to $10,211 for TMO. Over the past 12 months, TMO leads with a +16.6% total return vs LH's +6.5%. The 3-year compound annual growth rate (CAGR) favors LH at 11.6% vs TMO's -4.2% — a key indicator of consistent wealth creation.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +2.4% | -20.1% |
| 1-Year ReturnPast 12 months | +6.5% | +16.6% |
| 3-Year ReturnCumulative with dividends | +38.8% | -11.9% |
| 5-Year ReturnCumulative with dividends | +12.2% | +2.1% |
| 10-Year ReturnCumulative with dividends | +150.9% | +229.1% |
| CAGR (3Y)Annualised 3-year return | +11.6% | -4.2% |
LH leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
LH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LH is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LH currently trades 87.5% from its 52-week high vs TMO's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.52x | 1.10x |
| 52-Week HighHighest price in past year | $293.72 | $643.99 |
| 52-Week LowLowest price in past year | $239.67 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +87.5% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 40.5 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 579K | 1.9M |
LH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — LH and TMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates LH as "Buy" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs 21.2% for LH (target: $311). For income investors, LH offers the higher dividend yield at 1.12% vs TMO's 0.36%.
| Metric | LHLabcorp Holdings … | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $311.33 | $654.67 |
| # AnalystsCovering analysts | 35 | 42 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 8 |
| Dividend / ShareAnnual DPS | $2.87 | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.1% | +1.7% |
Evenly matched — LH and TMO each lead in 1 of 2 comparable metrics.
Key Takeaway
LH leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). TMO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallLabcorp Holdings Inc. (LH)Leads 4 of 6 categories
Loading custom metrics...
LH vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is LH or TMO a better buy right now?
For growth investors, Labcorp Holdings Inc.
(LH) is the stronger pick with 7. 2% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Labcorp Holdings Inc. (LH) offers the better valuation at 24. 6x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Labcorp Holdings Inc. (LH) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LH or TMO?
On trailing P/E, Labcorp Holdings Inc.
(LH) is the cheapest at 24. 6x versus Thermo Fisher Scientific Inc. at 26. 7x. On forward P/E, Labcorp Holdings Inc. is actually cheaper at 14. 5x.
03Which is the better long-term investment — LH or TMO?
Over the past 5 years, Labcorp Holdings Inc.
(LH) delivered a total return of +12. 2%, compared to +2. 1% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus LH's +150. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LH or TMO?
By beta (market sensitivity over 5 years), Labcorp Holdings Inc.
(LH) is the lower-risk stock at 0. 52β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 111% more volatile than LH relative to the S&P 500. On balance sheet safety, Thermo Fisher Scientific Inc. (TMO) carries a lower debt/equity ratio of 76% versus 83% for Labcorp Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LH or TMO?
By revenue growth (latest reported year), Labcorp Holdings Inc.
(LH) is pulling ahead at 7. 2% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Labcorp Holdings Inc. grew EPS 18. 3% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, LH leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LH or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 6. 3% for Labcorp Holdings Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 10. 9% for LH. At the gross margin level — before operating expenses — TMO leads at 37. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LH or TMO more undervalued right now?
On forward earnings alone, Labcorp Holdings Inc.
(LH) trades at 14. 5x forward P/E versus 19. 0x for Thermo Fisher Scientific Inc. — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.
08Which pays a better dividend — LH or TMO?
All stocks in this comparison pay dividends.
Labcorp Holdings Inc. (LH) offers the highest yield at 1. 1%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).
09Is LH or TMO better for a retirement portfolio?
For long-horizon retirement investors, Labcorp Holdings Inc.
(LH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52), 1. 1% yield, +150. 7% 10Y return). Both have compounded well over 10 years (LH: +150. 7%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LH and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
LH pays a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(LH: 5.8% · TMO: 6.2%)Net Margin>
%
(LH: 6.7% · TMO: 15.2%)P/E Ratio<
x
(LH: 24.6x · TMO: 26.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.